Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIMINATE-B: PBGENE-HBV in Chronic Hepatitis B
NCT06680232Phase 1Recruiting
- Sponsor
- Precision BioSciences, Inc.
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of PBGENE-HBV in Chronic Hepatitis B (CHB), sponsored by Precision BioSciences, Inc. Primary endpoint: Treatment-emergent Adverse Events at 4 weeks. Started Nov 2024; status: recruiting.
02
Drugs
PBGENE-HBV
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06680232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680232.